2021 Yearbook

02/24/2024 03:29:03
  • Home | Improving safety for multiple drug regimes 
  • In this issue
  • Contents
  • Curtis Health Caps
  • Astrix
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Covid-19 executive briefing by GlobalData
  • Owen Mumford Company Insight
  • Owen Mumford
  • Comment
  • Use of AI in the fight against Covid-19 shows mixed results
  • What does Ireland’s tax hike mean for pharma?
  • Chinese review designations lag behind US and EU
  • The business benefits of text mining in life sciences
  • Mettler Toledo
  • HOF Sonderanlagenbau
  • In Depth
  • Narrow FDA panel vote on Merck’s molnupiravir bolsters outlook on mAbs
  • The challenges of multiple drugs safety reporting
  • 3D printing in drug manufacturing: unlocking future possibilities
  • Can drug repurposing uncover better treatments for UTIs?
  • Pfizer and Takeda deals put a spotlight on value-based pricing
  • Lethal injection: can pharma kill the death penalty?
  • Mimotopes Company Insight
  • Mimotopes
  • In Data
  • Middle-income countries’ healthcare sectors to keep rising through to 2024
  • Data analytics hiring levels in clinical trial operations rose in October
  • Industrial automation innovation in pharma rebounded in the last quarter
  • Global markets and indices
  • Macro-economic indicators
  • Macro-economic indicators (page 2)
  • Yearbook
  • SHL Medical
  • Dr. Paul Lohmann Company Insight
  • Dr. Paul Lohmann
  • Novo Nordisk
  • Nipro
  • Events
  • Next issue
12/15/2021 00:00:00